Assignee
NAMMI THERAPEUTICS INC
US·8 granted patents·11 pending applications·4 citations·filing 2020–2025
Top patents by PatentIndex Score
19 records- 0192US11896646B2Formulated and/or co-formulated liposome compositions containing toll-like receptor (“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereofNAMMI THERAPEUTICS INC·Filed 2022·Granted Feb 13, 2024·1 cites·16 claims
- 0287US11679141B2Formulated and/or co-formulated liposome compositions containing toll-like receptor (“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereofNAMMI THERAPEUTICS INC·Filed 2021·Granted Jun 20, 2023·1 cites·9 claims
- 0386US11744874B2Formulated and/or co-formulated liposome compositions containing toll-like receptor (“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereofNAMMI THERAPEUTICS INC·Filed 2020·Granted Sep 5, 2023·1 cites·9 claims
- 0485US12311010B2Formulated and/or co-formulated liposome compositions containing toll-like receptor(“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereofNAMMI THERAPEUTICS INC·Filed 2023·Granted May 27, 2025·0 cites·14 claims
- 0585US11801304B2Formulated and/or co-formulated liposome compositions containing TFGB antagonist prodrugs useful in the treatment of cancer and methods thereofNAMMI THERAPEUTICS INC·Filed 2021·Granted Oct 31, 2023·1 cites·14 claims
- 0685US2024123028A1Formulated and/or Co-Formulated Liposome Compositions Containing Toll-Like Receptor ("TLR") Agonist Prodrugs Useful In The Treatment of Cancer and Methods Thereof CNAMMI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0782US2023277621A1Formulated and/or co-formulated liposome compositions containing toll-like receptor ("TLR") agonist prodrugs useful in the treatment of cancer and methods thereofNAMMI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0879US12059470B2Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereofNAMMI THERAPEUTICS INC·Filed 2023·Granted Aug 13, 2024·0 cites·18 claims
- 0978US2025032620A1Formulated and/or Co-Formulated Nanocarrier Compositions Containing TFGß Antagonist Prodrugs Useful in the Treatment of Cancer and Methods ThereofNAMMI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1076US2024366772A1Formulated and/or Co-Formulated Liposome Compositions Containing PD-1 Antagonist Prodrugs Useful in the Treatment of Cancer and Methods ThereofNAMMI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1175US2025313531A1Formulated and/or Co-Formulated Liposome Compositions Containing IDO Antagonist Prodrugs Useful in the Treatment of Cancer and Methods ThereofNAMMI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1275US2025177484A1Formulated and/or Co-Formulated Liposome Compositions Containing Toll-Like Receptor (TLR) Agonist Prodrugs Useful in the Treatment of Cancer and Methods ThereofNAMMI THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1375US2024050575A1Formulated and/or co-formulated liposome compositions containg TGFb antagonist prodrugs useful in the treatment of cancer and methods thereofNAMMI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1473US11833209B2Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereofNAMMI THERAPEUTICS INC·Filed 2021·Granted Dec 5, 2023·0 cites·15 claims
- 1568US12286403B2Formulated and/or co-formulated liposome compositions containing IDO antagonist prodrugs useful in the treatment of cancer and methods thereofNAMMI THERAPEUTICS INC·Filed 2020·Granted Apr 29, 2025·0 cites·19 claims
- 1662US2024108732A1Formulated and/or Co-Formulated Lipid Nanocarriers Compositions Containing Toll-Like Receptor ("TLR") Agonist Prodrugs Useful In The Treatment of Cancer and Methods ThereofNAMMI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1759US2025325634A1Fusion Protein Composition(s) Comprising Masked Type I Interferons (IFNa and IFNb) For Use in the Treatment of Cancer and Methods ThereofNAMMI THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1858US2023226031A1Formulated and/or Co-Formulated Liposome Compositions Containing Immunogenic Cell Death (ICD) Inducing Prodrugs Useful In The Treatment of Cancer and Methods ThereofNAMMI THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1957US2022401451A1Formulated and/or co-formulated compositions containing A2aR antagonist prodrugs useful in the treatment of cancer and methods thereofNAMMI THERAPEUTICS INC·Filed 2022·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →